போஹெரிங்கர் இஂகல்‌ஹைம் எலி லில்லி News Today : Breaking News, Live Updates & Top Stories | Vimarsana

May 19, 2021 Current guidelines strongly recommend use of the therapy for cardiology, diabetes patients In a series of presentations at ACC.21, the virtual meeting of the American College of Cardiology, researchers delivered data to confirm two observations about cardiovascular outcomes in heart failure patients with or without type 2 diabetes (T2D) and/or chronic kidney disease (CDK). First, the use of SGLT2 inhibitors is associated with reduced risk of cardiovascular death, worsening heart failure, and/or hospitalization for heart failure, and second, SGLT2i agents are woefully underused. In a presentation titled, “Just Go With the Flo(zin): SGLT2i Should Be Added to A Few, Some, Most, All HFrEF Patients?”, Glenn Herrington, PharmD, Ambulatory Care Cardiology Pharmacist at New Hanover Regional Medical Center in Wilmington, North Carolina, reviewed findings from EMPA-REG OUTCOME, CANVAS PROGRAM,DECLARE-TIMI 58, VERTIS CV, DAPA-HF, and EMPEROR-REDUCED to assess benefits and

United statesNorth carolinaSouth koreaMichaelj blahaGlenn herringtonRishav adhikaiPeggy peckBoehringer ingelheim eli lillyWayne huey herng sheuAmerican heart associationAmerican college of cardiologyAmerican diabetes associationJohns hopkins university school of medicineNational prescription auditAetna foundationCompany diabetes alliance